M31.31, Wegener's granulomatosis with renal involvementICD-10-CM
No Prior Auth Required
Covered without prior authorization by at least one policy, though another does not cover it (medium confidence)
WPS-J5-L37205, Chemotherapy Drugs and their Adjuncts
J5
A57554, Billing and Coding: Immune Globulins
J5
A57592, Billing and Coding: Non-Invasive Cerebrovascular Studies
J5
A57593, Billing and Coding: Non-Invasive Peripheral Arterial Vascular Studies
J5
A55639, Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions
J5
A59434, Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
J5
WPS-J5-L34771, Immune Globulins
J5
WPS-J5-L35753, Non-Invasive Cerebrovascular Studies
J5
WPS-J5-L35761, Non-Invasive Peripheral Arterial Vascular Studies
J5
NGS-J6-L39297, Off-label Use of Rituximab and Rituximab Biosimilars
J6
A52423, Billing and Coding: Infliximab and biosimilars
J6
A58893, Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
J6
NGS-J6-L33394, Drugs and Biologicals, Coverage of, for Label and Off-Label Uses
J6
A59101, Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars
J6
WPS-J8-L35761, Non-Invasive Peripheral Arterial Vascular Studies
J8
WPS-J8-L34771, Immune Globulins
J8
WPS-J8-L35753, Non-Invasive Cerebrovascular Studies
J8
WPS-J8-L37205, Chemotherapy Drugs and their Adjuncts
J8
A59764, Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
J9
FIRST_COAST-L36767, Aortography and peripheral angiography
J9
Ask Backwork about documentation requirements, denial risks, or coverage in your state.